王红宇, 王红, 沈松颖, 等. 伴急性肾损伤的DBD供肾肾移植的临床结局[J]. 器官移植, 2024, 15(4): 622-629. DOI: 10.3969/j.issn.1674-7445.2024027
引用本文: 王红宇, 王红, 沈松颖, 等. 伴急性肾损伤的DBD供肾肾移植的临床结局[J]. 器官移植, 2024, 15(4): 622-629. DOI: 10.3969/j.issn.1674-7445.2024027
Wang Hongyu, Wang Hong, Shen Songying, et al. Clinical outcome of kidney transplantation from DBD donors complicated with acute kidney injury[J]. ORGAN TRANSPLANTATION, 2024, 15(4): 622-629. DOI: 10.3969/j.issn.1674-7445.2024027
Citation: Wang Hongyu, Wang Hong, Shen Songying, et al. Clinical outcome of kidney transplantation from DBD donors complicated with acute kidney injury[J]. ORGAN TRANSPLANTATION, 2024, 15(4): 622-629. DOI: 10.3969/j.issn.1674-7445.2024027

伴急性肾损伤的DBD供肾肾移植的临床结局

Clinical outcome of kidney transplantation from DBD donors complicated with acute kidney injury

  • 摘要:
      目的  探讨伴急性肾损伤(AKI)的脑死亡器官捐献(DBD)供者供肾肾移植的临床结局。
      方法  回顾性分析216例DBD供者的资料,按照改善全球肾脏病预后组织(KDIGO)标准将分为AKI组(69例)与正常组(147例),AKI组进一步分为KDIGO 1期和2~3期两组,AKI组受者135例,正常组受者288例。总结受者术后肾功能恢复情况及临床结局。分析移植物功能延迟恢复(DGF)发生的危险因素。
      结果  AKI组供者血清肌酐(Scr)最高值、获取前Scr值、血钠最高值、获取前血钠值均高于正常组,升压药物应用时间长于正常组,48 h内液体复苏用量高于正常组,入院HCO3值低于正常组,尿崩症、低血压发生率高于对照组;KDIGO 2~3期供者Scr最高值、获取前Scr值较KDIGO 1期供者高(均为P<0.05)。与正常组比较,AKI组受者DGF、急性排斥反应发生率较高,行连续性肾脏替代治疗的比例较高,术后90 d内Scr水平较高,术后3 d尿量较少;与KDIGO 1期受者比较,KDIGO 2~3期受者术后3、4、5、15 d Scr水平较高,术后2 d尿量较少(均为P<0.05)。单因素分析结果显示供者年龄、Scr最高值、血钠最高值、48 h内液体复苏用量是肾移植术后受者发生DGF的危险因素,多因素分析结果显示,供者年龄是肾移植术后受者发生DGF的独立危险因素(均为P<0.05)。
      结论  伴AKI的DBD供者供肾用于肾移植,经过积极的器官维护可纠正AKI,对术后6个月移植物功能和存活率没有影响,可达到与非AKI供肾同样的效果,可作为扩大供肾来源。

     

    Abstract:
      Objective  To evaluate the clinical outcome of kidney transplantation from donation after brain death (DBD) donors complicated with acute kidney injury (AKI).
      Methods  Clinical data of 216 DBD donors were retrospectively analyzed, and they were divided into the AKI group (n=69) and control group (n=147) according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Donors in the AKI group were further divided into the KDIGO stage 1 and stage 2-3 subgroups. One hundred and thirty-five recipients were assigned into the AKI group and 288 recipients in the control group. Postoperative recovery of renal function and clinical outcomes of the recipients were recorded. The risk factors of delayed graft function (DGF) were identified.
      Results  The highest serum creatinine (Scr) level, Scr level before procurement, the highest blood sodium level and blood sodium level before procurement in the AKI group were higher than those in the control group. The application duration of vasopressors in the AKI group was longer than that in the control group. In the AKI group, the amount of fluid resuscitation within 48 h was higher, the HCO3 level at admission was lower, and the incidence of diabetes insipidus and hypotension was higher than those in the control group. The highest Scr level and the Scr level before procurement in KDIGO stage 2-3 donors were significantly higher than those in KDIGO stage 1 counterparts (all P<0.05). Compared with the control group, the incidence of DGF and acute rejection was higher, the proportion of continuous renal replacement therapy was higher, the Scr level within postoperative 90 d was higher, and the urine amount within postoperative 3 d was less than those of recipients in the AKI group. Compared with KDIGO stage 1 recipients, KDIGO stage 2-3 recipients had higher Scr levels at postoperative 3, 4, 5 and 15 d, and less urine amount at postoperative 2 d (all P<0.05). Univariate analysis showed that donor age, the highest Scr level, the highest blood sodium level and the amount of fluid resuscitation within 48 h were the risk factors for DGF in recipients after kidney transplantation. Multivariate analysis showed that donor age was the independent risk factor for DGF in recipients after kidney transplantation (all P<0.05).
      Conclusions  For the application of DBD donors complicated with AKI, active organ maintenance should be performed to alleviate AKI. It exerts no effect upon graft function and survival rate at postoperative 6 months, which may achieve equivalent efficacy as non-AKI donors and may be used as a source of extended criteria donor kidneys.

     

/

返回文章
返回